Recent Updates
Recently added Catalysts
ELDN Positive Sentiment Score: 70/100

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Wednesday, September 20, 2023 1 min read
Key Takeaway: Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced its participation in the Cantor Fitzgerald Global Healthcare Conference scheduled for September 27, 2023. During the event, CEO David-Alexandre C. Gros, M.D., and President Steve Perrin, Ph.D., will present on the company's initiatives. Eledon focuses on developing therapies to address organ transplant rejection and amyotrophic lateral sclerosis (ALS), with their lead compound being tegoprubart. The conference participation highlights the company's commitment to advancing their pipeline and engaging with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is actively participating in a significant healthcare conference.
  • Management's involvement indicates confidence in their therapeutic developments.
  • The company is developing innovative therapies for organ transplant rejection and ALS.

Full Press Release Details

IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a panel presentation at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023, at 8:00 a.m. ET.
To register in advance for the panel presentation webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
stephen@gilmartinir.com
Berry & Company Public Relations
Source: Eledon Pharmaceuticals

Tags

Frequently Asked Questions

When is Eledon's panel presentation at the conference?

Eledon's panel presentation is on September 27, 2023, at 8:00 a.m. ET.

Who will represent Eledon at the panel presentation?

David-Alexandre C. Gros, M.D. and Steve Perrin, Ph.D. will represent Eledon.

How can I access the webcast replay of the panel?

The replay will be available on Eledon's Events page after the live session.

What is Eledon's lead compound in development?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody.

What is Eledon's focus area in biotechnology?

Eledon focuses on organ transplant protection and treating amyotrophic lateral sclerosis.

Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals Cantor Fitzgerald Conference tegoprubart ALS biotechnology
Last updated: Sep 20, 2023